Guidance
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
NICE advice
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
Published advice on this topic (4)
- New advice in the last 6 months (0)
- Updated advice in the last 6 months (0)
- In development advice (0)
Quality standards
Set out priority areas for quality improvement in health and social care.
Published quality standards on this topic (2)
- New quality standards in the last 6 months (0)
- Updated quality standards in the last 6 months (0)
- In development quality standards (0)
Guidance by programme
-
NICE guidelines (4)
Review the evidence across broad health and social care topics.
-
Technology appraisal guidance (211)
Reviews the clinical and cost-effectiveness of new treatments.
-
Diagnostics guidance (1)
Review new diagnostic technologies for adoption in the NHS.
-
Health technology evaluation (1)
Review evidence to support adoption of health technologies in the NHS.
-
Interventional procedures guidance (1)
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
Advice by programme
-
Evidence summaries (1)
Review the best available evidence for selected medicines.
-
Medtech innovation briefings (3)
Review the evidence and likely costs of medical devices and technologies.
Products being developed or updated
-
In consultation (1)
Guidance and quality standards open for consultation.
-
In development (45)
Guidance, quality standards and advice being developed.
-
Awaiting development (34)
Guidance and quality standards awaiting development.
-
Topic selection (2)
Guidance in topic selection.
Get involved
Comment on guidance in development
Current guidance in consultation
News on this topic
Around 100,000 fewer colonoscopies expected to take place each year following updated NICE guidance
Tens of thousands of people a year could be spared the need for a colonoscopy following new guidance from NICE.
Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE
NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more data can be collected while patients can access the treatment.
Putting guidance into practice
Shared learning
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 3 of 3 shared learning examples for this topic:
-
Symptomatic Breast Referral Resource Suite: Enhancing the Suspected Cancer Recognition and Referral Process
-
GatewayC: Improving early detection of cancer through e-learning for primary care
-
Overcoming the challenges of implementing the new NICE guidance for suspected cancer: recognition and referral